Chinese growth is widely considered a possible enginefor reinvigorating the ailing global economy

Chinese growth is widely considered a possible enginefor reinvigorating the ailing global economy. Actual results could differmaterially from these current expectations and projections, and from historicalperformance.Humanetics CorporationPam Pettinella, Copyright Business Wire 2009. SAO PAULO, July 13 (Reuters) – Brazilian equities declinedon Monday as investors awaited key data later in the week thatcould clarify the outlook for economic recovery around theworld. These forward-looking statements are based onthe company`s current views and assumptions. For more information, visit: http:// This press release contains discussion of certain expectations regardingHumanetics` future performance.

The company focuses on the rapid discovery, developmentand commercialization of bioactive compounds for the prevention and treatment ofdiseases in categories with urgent and unmet needs. Humanetics has proprietarycompounds in clinical and pre-clinical stages of development in the areas ofradiation countermeasures, Alzheimer`s disease, post-traumatic stress disorderand obesity. About Humanetics CorporationHumanetics is a privately-held specialty pharmaceutical company headquartered inMinneapolis, Minnesota. NIC5-15 is different from many of the gamma-secretase inhibitors in that it is anatural compound, rather than a new chemical entity.

Preclinical studiesdemonstrated that NIC5-15 worked directly to prevent accumulation of amyloidplaque in the brain. Thecost of caring for the current Alzheimer`s population is estimated to be $100billion per year. There are no FDA-approved Alzheimer`s disease modifying drugs available today.Current drugs approved for use help maintain cognitive function, but only for alimited time. NIC5-15 is part of a new class of drugs known as gamma-secretaseinhibitors that are thought to prevent the formation or increase of amyloidplaque in the brain, now recognized as an important biomarker for Alzheimer`sdisease The NIH is providing research support in this area. We believe that intervention with NIC5-15 can make a significantdifference in people`s lives, and we are hopeful that these preliminarylearnings will be supported in subsequent clinical trials.” Phase IIB clinical trials on NIC5-15 will begin later this year under fundingsupport from both the National Institutes of Health and the Department ofVeterans Affairs. Alzheimer`s: A Devastating DiseaseAlzheimer`s disease affects 5.2 million Americans and another 5 million withearly-stage disease Nearly a half million new cases are reported annually.

“We are encouraged by these preliminary findings on NIC5-15,” said Ronald Zenk,President and CEO of Humanetics Corporation. “The ability to identify newtreatments that can modify the progression of Alzheimer`s disease is animportant milestone that Humanetics and Mount Sinai are working towards in thisresearch. These early findings suggest the need for furtherinvestigation of NIC5-15 in the treatment of Alzheimer`s disease.” The Phase IIA trial was sponsored by Minneapolis, MN-based HumaneticsCorporation which also has exclusive rights to develop and commercialize NIC5-15to treat Alzheimer`s disease. The Mount Sinai School of Medicine has provided toHumanetics certain intellectual property rights related to these studies fromwhich MSSM and Dr. Pasinetti, as Principal Investigator of the Phase IIA study,would be entitled to receive royalties from the sale of NIC5-15. Humanetics iscurrently seeking a pharmaceutical partner for FDA approval andcommercialization of the product. The double-blind placebo controlled pilot safety and efficacy study wasconducted by Mount Sinai investigators on patients with mild to moderateAlzheimer`s disease.

Patients, who had an average age of 70 years, were givenescalating oral doses of NIC5-15 over a 45-day period. Investigators collectedpreliminary evidence of treatment efficacy including cognitive and globalmeasures and secondary outcomes including activities of daily living, behavioraldisturbances, pharmacokinetic parameters and a number of Alzheimer`s diseasebiomarkers including Abeta peptide levels. and Hillel Grossman,M.D., both of Mount Sinai School of Medicine, each made a poster presentation onNIC5-15 at ICAD 2009 Dr. Pasinetti said his findings supported the conclusionthat “NIC5-15 is a safe and tolerable natural compound that may alleviateAlzheimer`s disease dementia through multiple mechanisms including Abetalowering activities. “Whether we develop or license new technologies, our goal is toremain the leader in providing innovative packaging solutions.”Lawrence J. UKFI — previously described by Moreno as a “Fidelity withnuclear weapons” in a reference to the large U.S.